Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner.

Abdelouahab H, Zhang Y, Wittner M, Oishi S, Fujii N, Besancenot R, Plo I, Ribrag V, Solary E, Vainchenker W, Barosi G, Louache F.

Oncotarget. 2016 Jul 22;8(33):54082-54095. doi: 10.18632/oncotarget.10789. eCollection 2017 Aug 15.

PMID:
28903325
2.

Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.

Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S.

J Hematol Oncol. 2012 Aug 1;5:43. doi: 10.1186/1756-8722-5-43. Review.

3.

Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition.

Prakash S, Hoffman R, Barouk S, Wang YL, Knowles DM, Orazi A.

Mod Pathol. 2012 Jun;25(6):815-27. doi: 10.1038/modpathol.2012.33. Epub 2012 Mar 2.

4.

Contrasting dynamic responses in vivo of the Bcl-xL and Bim erythropoietic survival pathways.

Koulnis M, Porpiglia E, Porpiglia PA, Liu Y, Hallstrom K, Hidalgo D, Socolovsky M.

Blood. 2012 Feb 2;119(5):1228-39. doi: 10.1182/blood-2011-07-365346. Epub 2011 Nov 15.

5.

Splenectomy normalizes hematocrit in murine polycythemia vera.

Mo JR, Mathur A, Angagaw M, Zhao S, Wang Y, Gargano D, DiBacco A, Bachman ES.

PLoS One. 2009 Sep 30;4(9):e7286. doi: 10.1371/journal.pone.0007286.

6.

The implication of identifying JAK2 ( V617F ) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis.

Olsen RJ, Dunphy CH, O'Malley DP, Rice L, Ewton AA, Chang CC.

J Hematop. 2008 Sep;1(2):111-7. doi: 10.1007/s12308-008-0014-8. Epub 2008 Aug 28.

Supplemental Content

Support Center